These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

771 related items for PubMed ID: 9793187

  • 1. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E, van Lith JM, Mol BW, Bleker OP, Bilardo CM.
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K, Nicolaides KH.
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [Abstract] [Full Text] [Related]

  • 6. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B, Sairam S, Michailidis G, Wathen NC.
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [Abstract] [Full Text] [Related]

  • 7. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
    Zoppi MA, Ibba RM, Floris M, Monni G.
    Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Increased nuchal translucency as a marker for fetal chromosomal defects.
    Taipale P, Hiilesmaa V, Salonen R, Ylöstalo P.
    N Engl J Med; 1997 Dec 04; 337(23):1654-8. PubMed ID: 9385124
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F, Dommergues M, Benattar C, Taieb J, Thalabard JC, Frydman R.
    Ultrasound Obstet Gynecol; 2001 Jul 04; 18(1):26-31. PubMed ID: 11489221
    [Abstract] [Full Text] [Related]

  • 17. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
    Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH.
    Lancet; 1998 Aug 01; 352(9125):343-6. PubMed ID: 9717920
    [Abstract] [Full Text] [Related]

  • 18. The use of nuchal translucency measurement and second trimester biochemical markers in screening for Down's syndrome.
    Michailidis GD, Spencer K, Economides DL.
    BJOG; 2001 Oct 01; 108(10):1047-52. PubMed ID: 11702836
    [Abstract] [Full Text] [Related]

  • 19. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units.
    Pandya PP, Goldberg H, Walton B, Riddle A, Shelley S, Snijders RJ, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1995 Jan 01; 5(1):20-5. PubMed ID: 7850584
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.